Ionis CSO Sells $1.7M as Stock Falls to $44 vs $84 Target
Three Ionis executives, including the Chief Scientific Officer, sold $2.6 million in shares at $83-$85 in July. The stock has since fallen 46% to $44.65, despite analyst consensus targets at $83.64 dr
Ionis Insiders Split as Phase 3 Results Whipsaw Stock
NEW YORK, September 30 —
Ionis Pharmaceuticals, Inc. (IONS) trades at $44.65, roughly half the price at which its Chief Scientific Officer liquidated $1.74 million in shares three months ago, even as clinical wins reported this week push the analyst consensus price target to $83.64. The insider ledger tells two stories, and both are currently losing.
- CSO Bennett sold $1.74M in shares at $83, $85 on July 7; net 90-day insider activity was -$1.58M.
- TTM revenue of $870M fell 40.7% year over year; operating cash burn was $496M against $2.10B in cash.
- Four consecutive EPS beats, most recently by 51.2%; gross margin is -6.9% on a GAAP basis.
When the Scientists Leave at $85
On July 7, 2026, Chief Scientific Officer C. Frank Bennett, Director Allene M. Diaz, and Chief Development Officer Holly B. Kordasiewicz all sold shares within a narrow $83.58, $85.46 range, generating combined proceeds of roughly $2.64 million. Ionis is an RNA-targeted medicines platform with seven approved drugs, including SPINRAZA for spinal muscular atrophy and WAINUA for hereditary polyneuropathy. Bennett alone sold 20,536 shares across two open-market transactions, not option exercises; these required active decisions at a specific price. Three senior figures in science, development, and governance selling in the same narrow price window is a pattern worth watching.
The Buyer at $53 and a Four-Year Runway
Three weeks after the July 7 sales, Director Michael R. Hayden bought 20,000 shares at $51.60, $53.38 on July 30-31, the day after Ionis filed its Q2 2026 earnings 8-K, for approximately $1.06 million. The stock has since fallen to $44.65, below his entry range. The financial case is demanding: trailing revenue fell 40.7%, and the $496 million annual operating cash burn leaves approximately four years of runway against the $2.10 billion cash position. Readers weighing the cash dynamics can stress-test assumptions with the DCF calculator.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IONS | $7.4B | n/a | -30.3% |
| ALNY | $33.0B | 19.8x | -44.8% |
| SRPT | $1.9B | 6.9x | -3.5% |
| AGIO | $2.0B | n/a | -16.9% |
| INCY | $24.6B | 13.7x | +42.1% |
| BMRN | $11.6B | 9.1x | +9.1% |
Clinical Volatility Hasn't Resolved the Insider Math
The clinical calendar has lurched in both directions since July. Ionis filed dual 8-Ks on September 4 around the time the stock dropped, a trial-miss headline landed around September 18, and coverage from September 27-30 described "fresh Phase 3 wins." Three active Phase 3 programs, including olezarsen for hypertriglyceridemia with cardiovascular disease and ION582 for Angelman syndrome, are the pipeline bet behind the $83.64 analyst consensus. Four consecutive EPS beats show the base business outperforms expectations; the next Phase 3 readouts will determine whether the pipeline converts fast enough to offset the $496 million annual cash burn. Run the free Ionis Pharmaceuticals, Inc. deep-dive → for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Ionis executives sell $2.6M in July?
Chief Scientific Officer C. Frank Bennett, Director Allene M. Diaz, and Chief Development Officer Holly B. Kordasiewicz sold $2.64 million in shares at $83-$85 on July 7. The timing preceded both clinical setbacks in September and subsequent Phase 3 wins, leaving the insider intent ambiguous.
How much cash does Ionis have left?
Ionis has $2.10 billion in cash but burns $496 million annually, providing approximately four years of runway. Whether the company survives depends on whether its pipeline converts at a pace that offsets the cash burn.
Why are analysts targeting $84 for a $44 stock?
The $83.64 consensus price target reflects Phase 3 clinical wins reported September 27-30 and four consecutive EPS beats, most recently by 51.2%. Analysts are betting on three active Phase 3 programs, including olezarsen for hypertriglyceridemia with cardiovascular disease and ION582 for Angelman syndrome, to convert successfully.
Is Ionis revenue growing?
No. Trailing twelve-month revenue fell 40.7% year over year, and gross margin is negative at -6.9% on a GAAP basis. However, four consecutive EPS beats suggest operational improvements despite the revenue headwinds.
What drugs does Ionis have approved?
Ionis has seven approved drugs including SPINRAZA for spinal muscular atrophy and WAINUA for hereditary polyneuropathy. The company is also pursuing three active Phase 3 programs that could expand its portfolio.
Ionis Pharmaceuticals trades at $44.65 — roughly half the price at which its Chief Scientific Officer sold $1.74 million in shares on July 7 — even as news from this week describes fresh Phase 3 wins and the analyst consensus price target stands at $83.64. A board director's $1.06 million open-market purchase three weeks after the July sell-off has not halted the slide, and the question is whether a fresh round of clinical wins can reverse a 40.7% revenue decline and $496 million annual operating cash burn.